Natixis Sells 5,602 Shares of CVS Health Co. (NYSE:CVS)

Natixis reduced its holdings in shares of CVS Health Co. (NYSE:CVS - Free Report) by 5.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 101,349 shares of the pharmacy operator's stock after selling 5,602 shares during the period. Natixis' holdings in CVS Health were worth $4,550,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. EagleClaw Capital Managment LLC increased its stake in shares of CVS Health by 3.4% during the 4th quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator's stock valued at $275,000 after acquiring an additional 200 shares during the last quarter. Manchester Capital Management LLC increased its holdings in shares of CVS Health by 4.8% during the 4th quarter. Manchester Capital Management LLC now owns 4,457 shares of the pharmacy operator's stock worth $200,000 after buying an additional 204 shares during the last quarter. Angeles Investment Advisors LLC grew its position in CVS Health by 3.7% during the fourth quarter. Angeles Investment Advisors LLC now owns 5,706 shares of the pharmacy operator's stock valued at $256,000 after acquiring an additional 204 shares during the period. Rogco LP grew its holdings in shares of CVS Health by 3.2% during the 4th quarter. Rogco LP now owns 6,752 shares of the pharmacy operator's stock worth $303,000 after purchasing an additional 210 shares during the period. Finally, Beck Mack & Oliver LLC grew its stake in CVS Health by 1.1% during the fourth quarter. Beck Mack & Oliver LLC now owns 20,425 shares of the pharmacy operator's stock worth $917,000 after buying an additional 232 shares during the period. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other CVS Health news, Director Michael F. Mahoney bought 30,000 shares of CVS Health stock in a transaction dated Tuesday, February 18th. The stock was bought at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the acquisition, the director now directly owns 39,356 shares of the company's stock, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP James David Clark sold 7,513 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now directly owns 8,394 shares of the company's stock, valued at approximately $556,941.90. This represents a 47.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.22% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on CVS. StockNews.com upgraded shares of CVS Health from a "sell" rating to a "hold" rating in a research note on Thursday, February 13th. Leerink Partners upgraded shares of CVS Health from a "market perform" rating to an "outperform" rating and upped their target price for the company from $55.00 to $75.00 in a research note on Thursday, February 13th. Wolfe Research lifted their target price on CVS Health from 67.00 to 70.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. Robert W. Baird increased their price objective on shares of CVS Health from $51.00 to $71.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 15th. Finally, Wells Fargo & Company upped their target price on CVS Health from $68.00 to $73.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Four analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, CVS Health presently has a consensus rating of "Moderate Buy" and a consensus target price of $71.83.

CVS Health Price Performance

CVS traded down $0.62 during trading on Friday, reaching $65.30. The stock had a trading volume of 5,020,541 shares, compared to its average volume of 11,808,423. CVS Health Co. has a 1-year low of $43.56 and a 1-year high of $71.45. The firm has a market capitalization of $82.33 billion, a price-to-earnings ratio of 17.84, a price-to-earnings-growth ratio of 0.98 and a beta of 0.57. The stock has a 50 day moving average of $66.49 and a two-hundred day moving average of $58.87. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. As a group, equities analysts anticipate that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be given a dividend of $0.665 per share. The ex-dividend date is Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.07%. CVS Health's dividend payout ratio (DPR) is presently 72.68%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.